Navigation Links
LS9's UltraClean Diesel™ Receives EPA Registration
Date:4/13/2010

Diesel Replacement Offers 85% Reduction in Carbon Footprint

(PRWEB) -- LS9, Inc., the Renewable Petroleum Company™, today announced that its UltraClean Diesel™, a diesel replacement product offering an 85% reduction in carbon footprint, was officially registered by the United States Environment Protection Agency (EPA). As a registered fuel, LS9’s UltraClean Diesel™ can be sold commercially in the United States.    

“This registration clears the way for LS9 to help reduce greenhouse gas emissions by bringing to market a low-carbon, advanced biofuel that can be used in today’s engines,” said Bill Haywood, LS9’s Chief Executive Officer. “This is yet another significant achievement for LS9 and a huge breakthrough for advanced biofuels.”

The chemical composition for LS9’s UltraClean Diesel™ is compatible with the existing infrastructure and has a more desirable environmental footprint than conventional diesel. Production of LS9 UltraClean Diesel™ provides an 85% reduction in greenhouse gas emissions when compared to conventional petroleum diesel. In addition, LS9 UltraClean Diesel™ is free of benzene, a common carcinogen, and contains only trace amounts or sulfur, both of which are generally associated with conventional diesel products.

LS9 is the low-cost producer of advanced biofuels products. LS9’s UltraClean Diesel™ is the only finished diesel replacement directly produced by fermentation of renewable raw materials in a single step. The company’s proprietary one-step process has higher yields and removes additional production costs associated with the multi-step processes required by other advanced biofuel technologies. LS9’s technology also results in superior products that are designed to optimize overall performance. LS9 genetically engineers microorganisms to precisely produce fuels with improved properties such as cetane, volatility, oxidative stability and cold-flow.

In addition to low-carbon transportation fuels, LS9’s proprietary one-step fermentation process is capable of producing high-value chemicals used in making industrial and consumer products.

About LS9
LS9, Inc., the Renewable Petroleum Company™, is a privately-held industrial biotechnology company pursuing the commercial development of renewable fuels and chemicals. LS9 is applying synthetic biology to produce proprietary biofuels that are compatible with existing fuel distribution and consumer infrastructure, as well as high-value industrial chemicals. LS9 is the pioneer in the commercial development of fermentation derived hydrocarbon biofuels and its patent-pending Renewable Petroleum™ products are custom engineered in the lab to address immediate market needs for clean energy alternatives to petroleum. The company was founded in 2005 and has received funding from Chevron Technology Ventures, Flagship Ventures, Khosla Ventures, and Lightspeed Venture Partners. The company has also entered into a strategic partnership with Procter & Gamble. LS9 is headquartered in South San Francisco, California. Additional information about LS9 products and capabilities is available at www.ls9.com.

###

Read the full story at http://www.prweb.com/releases/2010/04/prweb3867134.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related biology technology :

1. LS9's UltraClean Diesel Exceeds United States & Brazilian Fuels Specifications
2. Drug Safety Firm BioSoteria Receives 2009 Best of Business Award
3. Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals
4. Indiana Collaborative Receives $10.3 Million in Federal Stimulus Funds to Improve Healthcare through Information Technology
5. Advanced Life Sciences Receives FDA Guidance on Approval Pathway for Restanza in Community Acquired Bacterial Pneumonia and Biodefense Indications
6. MedShape Solutions, Inc. Announces Commercialization of SBIR Funded Technology: Receives Purchasing Preference in Federally Funded Hospitals and Health Care Facilities
7. Gems Sensors & Controls Receives ISO-13485:2003 Certification
8. BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5 million
9. Longhorn Vaccines & Diagnostics LLC Receives FDA Emergency Use Authorization (EUA) for the First 2009 H1N1 Influenza Assay to Include a Molecular Transport Medium (MTM)
10. Sanaria Inc. Receives Multi-Year U.S. NIH Phase II Small Business Innovation Research Grant to Develop a Genetically Attenuated Whole Parasite Malaria Vaccine
11. Oncolytics Biotech(R) Inc. Receives Approval from the U.K. MHRA to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... LINDA, CA (PRWEB) , ... October 11, 2017 ... ... to upregulate any gene in its endogenous context, enabling overexpression experiments and avoiding ... (CRISPRa) system with small RNA guides is transformative for performing systematic gain-of-function studies. ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 /PRNewswire/ ... London (ICR) and University of ... tool to risk-stratify patients with multiple myeloma (MM), in a ... . The University of Leeds is ... Myeloma UK, and ICR will perform the testing services to ...
(Date:10/10/2017)... Los Angeles, CA (PRWEB) , ... ... ... Pharmaceuticals, Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) ... all uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed ...
(Date:10/10/2017)... ... October 10, 2017 , ... USDM Life Sciences , ... life sciences and healthcare industries, announces a presentation by Subbu Viswanathan and Jennifer ... “Automating GxP Validation for Agile Cloud Platforms,” will present a revolutionary approach to ...
Breaking Biology Technology:
(Date:4/5/2017)... 5, 2017  The Allen Institute for Cell Science ... a one-of-a-kind portal and dynamic digital window into the ... the first application of deep learning to create predictive ... lines and a growing suite of powerful tools. The ... and future publicly available resources created and shared by ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/29/2017)... the health IT company that operates the largest health ... today announced a Series B investment from BlueCross BlueShield ... investment and acquisition accelerates higi,s strategy to create the ... activities through the collection and workflow integration of ambient ... secures data today on behalf of over 36 million ...
Breaking Biology News(10 mins):